Elham Kamran

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

The real-world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review.

The real-world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review.

Journal: Clinical obesity

Published: April 12, 2024

Healthcare utilization associated with obesity management in Ontario, Canada.

Healthcare utilization associated with obesity management in Ontario, Canada.

Journal: Clinical obesity

Published: January 17, 2024

Grazing and food addiction: Associations between varied patterns of overconsumption and addictive-like eating.

Grazing and food addiction: Associations between varied patterns of overconsumption and addictive-like eating.

Journal: Appetite

Published: December 20, 2023

Association between weight-loss history and weight loss achieved in clinical obesity management: Retrospective chart review.

Association between weight-loss history and weight loss achieved in clinical obesity management: Retrospective chart review.

Journal: Obesity (Silver Spring, Md.)

Published: February 08, 2022

An analysis of weight loss efforts and expectations in a Canadian Cohort: A retrospective medical chart review.

An analysis of weight loss efforts and expectations in a Canadian Cohort: A retrospective medical chart review.

Journal: Clinical obesity

Published: December 12, 2020

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.

Journal: International journal of obesity (2005)

Published: September 18, 2020

Sequential diets and weight loss: Including a low-carbohydrate high-fat diet with and without time-restricted feeding.

Sequential diets and weight loss: Including a low-carbohydrate high-fat diet with and without time-restricted feeding.

Journal: Nutrition (Burbank, Los Angeles County, Calif.)

Published: July 14, 2020

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada.

Journal: Obesity science & practice

Published: January 13, 2020

Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.

Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program.

Journal: Obesity science & practice

Published: December 04, 2019

The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review.

The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review.

Journal: Journal of drug assessment

Published: May 08, 2019

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery.

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery.

Journal: Clinical obesity

Published: May 01, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026